G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, ...
The FDA has granted priority review to the new drug application (NDA) for gedatolisib, a first-in-class multi-target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results